Hatch, Waxman Signal Concern About "Authorized Generics"
During a two-day Drug & Device Dialogue conference called “Following On Hatch-Waxman: Credentials for Success,” Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) hinted the impact of authorized generics on competition in the pharmaceutical sector is undermining the principles of the Hatch-Waxman Act.
"I think that's certainly an area that...
Already a subscriber? Click here to login